10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

TRIM58 Antibody

Catalog # ASC12033

Product Information

Application	WB, E
Primary Accession	Q8NG06
Other Accession	112421127, NP_056246, 25893
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	54766
Application Notes	TRIM58 antibody can be used for Western blot at 1 - 2 g/mL.

Additional Information

Gene ID	25893
Other Names	TRIM58 Antibody: Tripartite motif containing 58 protein, BIA2
Precautions	TRIM58 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TRIM58
Function	E3 ubiquitin ligase induced during late erythropoiesis. Directly binds and ubiquitinates the intermediate chain of the microtubule motor dynein (DYNC1LI1/DYNC1LI2), stimulating the degradation of the dynein holoprotein complex. May participate in the erythroblast enucleation process through regulation of nuclear polarization.
Tissue Location	Expressed in erythroblasts.


Background

TRIM58 Antibody: TRIM58 is a member of the tripartite motif-containing family of proteins that frequently possess E3 ubiquitin ligase activities (1). TRIM58 is strongly expressed in erythroid lineage cells and is further upregulated during late erythroid maturation. Recent experiments suggest that TRIM58 facilitates erythroblast enucleation by ubiquitinating the intermediate chain of the microtubule motor dynein, thereby inducing proteolytic degradation (2).

References

Napolitano LM and Meroni G. TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life 2012; 64:64-71.;Thom CS, Traxler EA, Khandros E, et al. Trim58 degrades dynein and regulates terminal erythropoiesis. Dev. Cell 2014; 30:688-700.;;

Images



Western blot analysis of TRIM58 in (A) human heart tissue and (B) mouse kidney lysate with TRIM58 antibody at 1 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.